BR0112637A - Sequências do vìrus do papiloma códon-otimizadas - Google Patents

Sequências do vìrus do papiloma códon-otimizadas

Info

Publication number
BR0112637A
BR0112637A BR0112637-7A BR0112637A BR0112637A BR 0112637 A BR0112637 A BR 0112637A BR 0112637 A BR0112637 A BR 0112637A BR 0112637 A BR0112637 A BR 0112637A
Authority
BR
Brazil
Prior art keywords
optimized
papilloma virus
virus
codon
virus sequences
Prior art date
Application number
BR0112637-7A
Other languages
English (en)
Inventor
Peter Franz Ertl
Gerald Wayne Gouch
Vanita Parmar
Christopher Jeffrey Alan Ring
Sarah Marina Walcott
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0017990.3A external-priority patent/GB0017990D0/en
Priority claimed from GB0025802A external-priority patent/GB0025802D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0112637A publication Critical patent/BR0112637A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"SEQ êNCIAS DO VìRUS DO PAPILOMA CóDON-OTIMIZADAS". A presente invenção está relacionada a métodos e composições úteis no tratamento e prevenção de infecções pelo vírus do papiloma humano e os sintomas e doenças associadas ao vírus. Mais particularmente, a invenção está relacionada a seq³ências de nucleotídeos que codificam às seq³ências de aminoácidos do vírus do papiloma humano (HVP) , onde o padrão de utilização do códon das seq³ências de polinucleótideos lembra os genes de mamiféros altamente expressados.
BR0112637-7A 2000-07-21 2001-07-20 Sequências do vìrus do papiloma códon-otimizadas BR0112637A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0017990.3A GB0017990D0 (en) 2000-07-21 2000-07-21 Papilloma virus sequences
GB0025802A GB0025802D0 (en) 2000-10-20 2000-10-20 Papilloma virus sequences
PCT/GB2001/003290 WO2002008435A1 (en) 2000-07-21 2001-07-20 Codon-optimized papilloma virus sequences

Publications (1)

Publication Number Publication Date
BR0112637A true BR0112637A (pt) 2003-06-10

Family

ID=26244703

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112637-7A BR0112637A (pt) 2000-07-21 2001-07-20 Sequências do vìrus do papiloma códon-otimizadas

Country Status (22)

Country Link
EP (1) EP1301614B1 (pt)
JP (1) JP2004504057A (pt)
KR (1) KR100874552B1 (pt)
CN (1) CN1262665C (pt)
AT (1) ATE346947T1 (pt)
AU (2) AU7569501A (pt)
BR (1) BR0112637A (pt)
CA (1) CA2416488A1 (pt)
CY (1) CY1106334T1 (pt)
CZ (1) CZ2003180A3 (pt)
DE (1) DE60124918T2 (pt)
DK (1) DK1301614T3 (pt)
ES (1) ES2277605T3 (pt)
HK (1) HK1056195B (pt)
HU (1) HUP0300745A3 (pt)
IL (1) IL154009A0 (pt)
MX (1) MXPA03000554A (pt)
NO (1) NO20030219L (pt)
NZ (1) NZ523683A (pt)
PL (1) PL365385A1 (pt)
PT (1) PT1301614E (pt)
WO (1) WO2002008435A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1800697B1 (de) * 2001-06-05 2010-04-14 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
US20050118139A1 (en) * 2001-08-23 2005-06-02 Lingyi Huang Vaccine using papilloma virus e proteins delivered by viral vector
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
EP1608767B1 (en) 2003-03-24 2012-02-22 Merck Sharp & Dohme Corp. Optimized expression of hpv 31 l1 in yeast
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
ATE466022T1 (de) 2004-03-24 2010-05-15 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
GB0700914D0 (en) * 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
KR101636575B1 (ko) 2007-01-30 2016-07-05 트랜스진 에스.에이. 유두종바이러스 백신
CA2682089C (en) 2007-03-30 2019-03-12 The Research Foundation Of State University Of New York Attenuated viruses useful for vaccines
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
WO2017015463A2 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
US10934525B2 (en) 2015-10-30 2021-03-02 Children's National Medical Center Generating HPV antigen-specific cells from a naive T cell population
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464936A (en) * 1990-12-21 1995-11-07 Cetus Oncology Corporation Compositions for identification of papillomavirus replication inhibitors
DE4123760C2 (de) * 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
DE69836206T2 (de) * 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
CA2342289C (en) * 1998-09-04 2012-07-24 Aventis Pasteur Limited Treatment of cervical cancer
DE60016765T2 (de) * 1999-08-25 2005-11-24 Merck & Co., Inc. Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind

Also Published As

Publication number Publication date
AU2001275695B2 (en) 2005-01-27
PT1301614E (pt) 2007-02-28
CN1262665C (zh) 2006-07-05
DK1301614T3 (da) 2007-04-02
EP1301614B1 (en) 2006-11-29
CZ2003180A3 (cs) 2003-08-13
MXPA03000554A (es) 2004-12-13
NZ523683A (en) 2004-08-27
DE60124918T2 (de) 2007-08-02
NO20030219L (no) 2003-03-20
PL365385A1 (en) 2005-01-10
HUP0300745A3 (en) 2010-01-28
WO2002008435A8 (en) 2002-04-04
KR100874552B1 (ko) 2008-12-16
ES2277605T3 (es) 2007-07-16
ATE346947T1 (de) 2006-12-15
WO2002008435A1 (en) 2002-01-31
HK1056195B (zh) 2007-06-22
NO20030219D0 (no) 2003-01-16
DE60124918D1 (de) 2007-01-11
KR20030074586A (ko) 2003-09-19
IL154009A0 (en) 2003-07-31
AU2001275695B9 (en) 2005-05-26
CA2416488A1 (en) 2002-01-31
JP2004504057A (ja) 2004-02-12
CN1462309A (zh) 2003-12-17
AU7569501A (en) 2002-02-05
EP1301614A1 (en) 2003-04-16
CY1106334T1 (el) 2011-10-12
HUP0300745A2 (hu) 2003-08-28
HK1056195A1 (en) 2004-02-06

Similar Documents

Publication Publication Date Title
BR0112637A (pt) Sequências do vìrus do papiloma códon-otimizadas
AU2001254624A1 (en) Human coagulation factor vii variants
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
BR9905902A (pt) Clone de cdna infeccioso do vìrus da sìndrome reprodutiva e respiratória de porcino norte-americana (prrs) e seus usos
AU2003264514A1 (en) Wt1 substitution peptides
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
BR9803960A (pt) Gene de desidrogenase de d-sorbitol.
TW200502246A (en) Vaccine
DK1383874T3 (da) Varianter af lipogygenase og deres anvendelse
CA2334941A1 (en) Tnf-derived peptides for use in treating oedema
EP1613345A4 (en) COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320
BR0111393A (pt) Métodos de tratamento de doenças virais com il-18 e suas combinações
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus
WO2001072977A3 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
SE1077068T3 (sv) Anvaendning av interferon-alfa-5 vid behandling av virus-hepatopatier
MXPA03010816A (es) ENZIMA DE DESCOMPOSICIoN DE SAPONINA, GEN DE LA MISMA Y SISTEMA DE PRODUCCIoN A GRAN ESCALA PARA LA PRODUCCIoN DE SOYASAPOGENOL B.
PT1254663E (pt) Agente antiviral
WO2002033058A3 (en) Novel cysteine proteases and uses thereof
WO2002016586A3 (en) Adenosine deaminase homolog
BR0207889A (pt) Proteìna, molécula de ácido nucleico codificando a mesma, molécula de ácido nucleico recombinante, hospedeiro de microorganismo transformado, processo para produzir uma aminopeptidase, e , aminopeptidase
WO2024020320A3 (en) Non-immunogenic circular, non-viral dna vectors
RU2004103078A (ru) Молекулы иммунного связывания, ингибирующие синцитиальное слияние клеток трофобласта
WO2000061750A3 (en) TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
ATE286535T1 (de) Regulatorisches protein pke 83 aus humanen keratinozyten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]